Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
about
Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained womenThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Gender differences in pharmacokinetics of maintenance dosed buprenorphine.Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancyPeripartum pain management in opioid dependent womenOpioid dependent and pregnant: what are the best options for mothers and neonates?Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.Evaluation of a Training to Reduce Provider Bias Toward Pregnant Patients With Substance Abuse.To Be Free and Normal: Addiction, Governance, and the Therapeutics of BuprenorphineShould pregnant women with substance use disorders be managed differently?Age-related aspects of addiction.Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics.Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes.Evaluation and management of opioid dependence in pregnancyBuprenorphine in the treatment of opiate dependence.Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women.Social defeat stress and escalation of cocaine and alcohol consumption: Focus on CRF
P2860
Q33862878-E12AFE19-2223-44B2-8C3B-494A96FB16ACQ33870389-17DA9912-604D-43B6-B2DA-EFB17381DC86Q35184385-598DAC35-956D-4F3A-B8BC-1CE79C4E494CQ35552420-F8FE14B3-4E41-4884-A559-BE9FD93F63F9Q35791067-E272C50F-0526-43D3-A81E-E69D6EBFAFE7Q35837987-F8676CE0-8717-4635-995A-E0E4B426F8DCQ35863900-86DD1AAC-1A34-469E-8497-3F4AEFEEF0DFQ35869839-75A4C97D-9768-477F-8CB7-D6A506A50627Q36399916-D50DD96E-191B-4CA8-8E2D-4E82BA0A69F7Q36464851-FF7DCF06-F6F4-4138-85D6-7A5C997E1A33Q36518313-7D1E0F3A-0A4D-4A4A-9C6B-50922D94E581Q36966035-5972D321-7985-4186-B003-0DCA444666EEQ37467788-139A4E1D-7FE3-4AA8-B86D-D6DEA33BD13DQ37632852-53A40DEE-EEB3-4506-AE02-1577B0037682Q42962930-D16D6FF4-4D58-4E49-AC64-1122A2FFE5ECQ44336832-01EBBE2C-432B-46F7-8430-398AC7E6DBDBQ59137249-B2366CBE-70D2-4CA7-BC85-3DCFFAAC8682
P2860
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
@ast
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
@en
type
label
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
@ast
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
@en
prefLabel
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
@ast
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
@en
P2093
P2860
P1476
Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.
@en
P2093
Annemarie Unger
Bernadette Winklbaur
Erika Jung
Gabriele Fischer
P2860
P304
P356
10.1080/10550881003684814
P577
2010-04-01T00:00:00Z